A recent report published by Infinium Global Research on metastatic breast cancer treatment market provides an in-depth analysis of segments and sub-segments in the global as well as regional metastatic breast cancer treatment market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional metastatic breast cancer treatment market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global metastatic breast cancer treatment market. According to the report, the global metastatic breast cancer treatment market is projected to grow at a CAGR of 9.6% over the forecast period of 2019-2025.
Cancer is a class of diseases that cause cells in the body to change and proliferate out of control. Breast cancer is the most primarily occurring cancer in women and the second most common cancer worldwide. In 2018, there were approximately 2.09 million new cases of breast cancer and 627000 deaths due to breast cancer. Metastatic breast cancer also is referred to as stage IV or advanced breast cancer. It is the most advanced stage of breast cancer. Metastatic breast cancer is breast cancer that has spread further on the breast to other organs such as bones, brain, liver or lungs. Despite the fact that metastatic breast cancer is viewed as an incurable disease with a poor prognosis, many people pursue to live long and productive lives with breast cancer in this stage. Cancer can be active and then go into remission or there can be recurrence at other times. There is a wide range of treatment alternatives for metastatic breast cancer, and new medicines are being assessed daily. Treatments can be used alone, in sequence or in combination.
The rising number of metastatic breast cancer cases due to increasing consumption of tobacco and alcohol, obesity, lack of physical activity, exposure to ionizing and ultraviolet radiation, and urban air pollution is driving the metastatic breast cancer treatment market globally. Initiatives taken by the government and NGOs to create awareness regarding metastatic breast cancer and its increasing survival rate due to technologically advanced treatments are boosting the market. Breast cancer in men is rare, with less than 1% of breast cancer cases in the US. Men at a greater extent than women are likely to be diagnosed with metastatic breast cancer, as a result of unawareness and late diagnosis as screening mammography is not suggested for men due to the rarity of the disease. Thus, poor prognosis is one of the factors estimated to increase the overall metastatic breast cancer treatment market. However, the high cost of the treatment and several side effects associated with the treatments hinders the growth of the market. Improving access to affordable care via health care reform, increasing clinical trials and funding for research in treatments opens further opportunities for the metastatic breast cancer treatment market.
The metastatic breast cancer treatment market covers geographical regions such as North-America, Europe, Asia-Pacific, and the Rest of the World. North-America accounts for the largest revenue followed by Europe due to increased diagnosis of disease and enhanced healthcare infrastructure. The Asia-pacific market is expected to increase during the forecast period as a result of improving reimbursement policies, large investments by market players in these regions as well as increased funding for treatment in low and middle-income regions.
The report on global metastatic breast cancer treatment market covers segments such as treatment type, and end user. On the basis of treatment type, the sub-markets include chemotherapy, radiation therapy, biologic targeted therapy, breast surgery, and hormone therapy. On the basis of end user, the sub-markets include hospitals, clinics, and other users.
The report provides profiles of the companies in the market such as F. Hoffmann-La Roche AG, Pfizer Inc., Novartis AG, Merck & Co., Inc., Eli Lilly and Company, GlaxoSmithKline Plc, Johnson and Johnson, AstraZeneca Plc, Bayer AG, Sun Pharmaceutical Industries Ltd, and Other companies.
The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of metastatic breast cancer treatment market. Moreover, the study highlights current market trends and provides forecast from 2019-2025. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.
Get free analyst support for the queries before and post purchasing report.
Be assured of 100% customer satisfaction about the research and get 24X7 customer support.
Infinium has achieved over 400%+ growth in its repository and revenue over the last 2 years. Yes, we are proud to say we are growing at a great pace and becoming a trusted partner among our clients.
sign up for our newsletter